Rocket Pharmaceuticals (RCKT) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

13

Hold

4

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.35

Median Target+79.10%

$6.00

Potential upside vs current price

DCF Value-85.85%

$0.47

Potential downside vs current price

Current Stock Price

$3.35

Median Target+79.10%

$6.00

Potential upside vs current price

DCF Value-85.85%

$0.47

Potential downside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

13

Hold

4

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$3.35

Median Target+79.10%

$6.00

Potential upside vs current price

DCF Value-85.85%

$0.47

Potential downside vs current price

Current Stock Price

$3.35

Median Target+79.10%

$6.00

Potential upside vs current price

DCF Value-85.85%

$0.47

Potential downside vs current price

Rocket Pharmaceuticals, Inc.